Skip to main content
Medical information Clinical review pending

Cytogenetics

Chromogranin A CGA Test

The Chromogranin A (CGA) Test measures levels of CGA in the blood to help detect and monitor neuroendocrine tumors. This test is important for individuals with symptoms or a history related to these types of cancers.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (serum)
Results
Confirm with the laboratory before booking. Samples are collected on Tuesdays and Fridays by 11 AM, with same-day reporting available.
Preparation
Patients should ideally discontinue proton pump inhibitor (PPI) medications at least 2 weeks before sample collection, if medically feasible. Confirm specific preparation instructions with the laboratory before booking.
Test priceKSh 20,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Chromogranin A CGA Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Suspected neuroendocrine tumor
  • ✓Monitoring response to treatment for neuroendocrine tumors
  • ✓Evaluating patients with symptoms potentially related to neuroendocrine tumors (e.g., flushing, diarrhea, abdominal pain)
  • ✓Family history of neuroendocrine tumors
02

In plain language

What this test helps you understand

The Chromogranin A (CGA) test is used as a biomarker to aid in the diagnosis and monitoring of neuroendocrine tumors (NETs). Elevated levels can suggest the presence of NETs, while decreasing levels can indicate response to treatment.
The Chromogranin A (CGA) Test is a diagnostic tool used to evaluate neuroendocrine tumors. These tumors can develop in various parts of the body, such as the pancreas, lungs, or gastrointestinal tract. Measuring CGA levels in the blood assists healthcare providers in diagnosing and monitoring these specific types of cancers.

This test specifically measures the concentration of Chromogranin A in a blood sample. Elevated levels of CGA can be an indicator of neuroendocrine tumors, potentially aiding in early detection and guiding treatment decisions.

Individuals who might be advised to consider this test include those experiencing symptoms like unexplained weight loss, abdominal pain, or hormonal changes, patients with a family history of neuroendocrine tumors, or those already diagnosed with certain cancers requiring monitoring.

Taking this test can offer several benefits, including the potential for early detection of neuroendocrine tumors, allowing for timely medical intervention. It also helps monitor how well treatment is working for patients already diagnosed and provides valuable information for doctors to manage patient care effectively.

Interpreting the results requires consultation with a healthcare provider. Generally, higher CGA levels may suggest the presence of neuroendocrine tumors, but normal levels do not completely rule out the condition. Your doctor will consider the results alongside your medical history and other tests to provide an accurate interpretation and recommend appropriate next steps.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationPatients should ideally discontinue proton pump inhibitor (PPI) medications at least 2 weeks before sample collection, if medically feasible. Confirm specific preparation instructions with the laboratory before booking.
SampleBlood sample (serum)
MethodologyImmunoassay (e.g., ELISA or Chemiluminescence)
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
Elevated CGA levels can also be seen in other conditions, such as renal failure, ectopic ACTH syndrome, and certain medications. False negatives can occur. This test is not specific for neuroendocrine tumors.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

Chromogranin A (CGA) is a protein found in neuroendocrine cells throughout the body. It is released into the bloodstream, and its levels can be elevated in the presence of neuroendocrine tumors.
This test helps doctors detect and monitor neuroendocrine tumors, which are relatively rare cancers. Early detection and monitoring are crucial for effective management.
Elevated CGA levels may suggest the presence of a neuroendocrine tumor, but further investigation is needed for diagnosis. Your doctor will interpret the results based on your overall health and other tests.
Fasting is generally not required, but it is important to inform the laboratory about any medications you are taking, especially proton pump inhibitors (PPIs).
A blood sample is collected from your arm.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp